Get the Stockscreener App
1.08
2.70%
-0.03
After Hours:
1.09
0.01
+0.93%
Geron Corp stock is traded at $1.08, with a volume of 7.98M.
It is down -2.70% in the last 24 hours and down -10.00% over the past month.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
See More
Previous Close:
$1.11
Open:
$1.11
24h Volume:
7.98M
Relative Volume:
1.10
Market Cap:
$689.06M
Revenue:
$29.48M
Net Income/Loss:
$-201.19M
P/E Ratio:
-3.375
EPS:
-0.32
Net Cash Flow:
$-216.50M
1W Performance:
-12.90%
1M Performance:
-10.00%
6M Performance:
-22.30%
1Y Performance:
-71.50%
1-Day Range:
$1.05
$1.12
1-Week Range:
$1.05
$1.245
52-Week Range:
$1.04
$4.205
Geron Corp Stock (GERN) Company Profile
Name
Geron Corp
Sector
Industry
Phone
(650) 473-7700
Address
919 EAST HILLSDALE BOULEVARD, FOSTER CITY, CA
Compare GERN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GERN
Geron Corp
|
1.08 | 708.57M | 29.48M | -201.19M | -216.50M | -0.32 |
|
VRTX
Vertex Pharmaceuticals Inc
|
421.03 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
702.75 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.76 | 61.08B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
914.59 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
203.56 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
Geron Corp Stock (GERN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-10-25 | Resumed | Goldman | Sell |
| May-08-25 | Downgrade | Scotiabank | Sector Outperform → Sector Perform |
| Feb-27-25 | Downgrade | B. Riley Securities | Buy → Neutral |
| Feb-26-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-05-24 | Initiated | H.C. Wainwright | Buy |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Initiated | Leerink Partners | Outperform |
| Apr-30-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-29-24 | Initiated | TD Cowen | Buy |
| Mar-15-24 | Reiterated | Needham | Buy |
| Sep-12-23 | Upgrade | Goldman | Neutral → Buy |
| Mar-28-23 | Initiated | Goldman | Neutral |
| Oct-28-22 | Initiated | Wedbush | Outperform |
| Jul-28-22 | Resumed | B. Riley Securities | Buy |
| Nov-02-21 | Initiated | Robert W. Baird | Outperform |
| Feb-18-21 | Resumed | B. Riley Securities | Buy |
| Aug-03-20 | Initiated | Stifel | Buy |
| Nov-19-19 | Resumed | B. Riley FBR | Buy |
| Sep-03-19 | Initiated | H.C. Wainwright | Buy |
| Aug-15-19 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-09-19 | Upgrade | Needham | Hold → Buy |
| Jan-31-19 | Upgrade | B. Riley FBR | Neutral → Buy |
| Oct-02-18 | Downgrade | B. Riley FBR | Buy → Neutral |
| Jul-05-18 | Initiated | B. Riley FBR, Inc. | Buy |
| Sep-13-16 | Reiterated | FBR & Co. | Outperform |
| Sep-13-16 | Reiterated | FBR Capital | Outperform |
| Dec-07-15 | Reiterated | Piper Jaffray | Overweight |
| Apr-21-15 | Initiated | Oppenheimer | Outperform |
| Jun-12-14 | Upgrade | MLV & Co | Hold → Buy |
| Mar-12-14 | Downgrade | MLV & Co | Buy → Hold |
| Dec-10-13 | Reiterated | MLV & Co | Buy |
| Dec-10-13 | Upgrade | Needham | Hold → Buy |
| Nov-08-13 | Reiterated | MLV & Co | Buy |
| Oct-16-13 | Initiated | MLV & Co | Buy |
| Aug-30-12 | Initiated | Stifel Nicolaus | Buy |
| Jun-28-12 | Initiated | Needham | Hold |
View All
Geron Corp Stock (GERN) Latest News
Will Geron Corporation stock rally after Fed decisionsGDP Growth & Community Verified Trade Signals - newser.com
Will Geron Corporation (GON) stock extend growth story2025 Breakouts & Breakdowns & Free Expert Approved Momentum Trade Ideas - newser.com
Published on: 2025-11-19 10:47:42 - newser.com
Why Geron Corporation (GON) stock remains stable2025 Risk Factors & Expert Approved Trade Ideas - newser.com
Why Geron Corporation (GON) stock stays on buy listsJuly 2025 Institutional & High Conviction Buy Zone Picks - newser.com
Why Geron Corporation (GON) stock is trending on social mediaWeekly Profit Report & Verified Technical Trade Signals - newser.com
Will Geron Corporation stock outperform growth indexesRate Hike & High Yield Equity Trading Tips - newser.com
Will Geron Corporation stock deliver strong dividend growth2025 Market Outlook & Verified Swing Trading Watchlist - newser.com
Published on: 2025-11-16 22:14:00 - newser.com
Published on: 2025-11-16 13:58:39 - newser.com
What hedge fund activity signals for Geron Corporation stockJuly 2025 EndofMonth & Precise Entry and Exit Recommendations - newser.com
Why Geron Corporation stock remains on watchlistsTrade Volume Report & Verified Entry Point Signals - newser.com
Published on: 2025-11-14 23:47:36 - newser.com
Can Geron Corporation (GON) stock resist broad market declinesJuly 2025 News Drivers & Real-Time Buy Signal Alerts - newser.com
How Geron Corporation stock performs in stagflationTrade Analysis Summary & Weekly Market Pulse Updates - newser.com
Can Geron Corporation (GON) stock attract analyst upgradesWeekly Trade Analysis & Technical Buy Zone Confirmations - newser.com
Why analysts maintain buy rating on Geron Corporation (GON) stockTrade Entry Report & Entry Point Strategy Guides - newser.com
What consensus target says about Geron Corporation (GON) stockJuly 2025 PostEarnings & Risk Controlled Stock Pick Alerts - newser.com
After a lackluster first drug launch, a new CEO is finding Geron’s commercial footing - Yahoo Finance
Is Geron Corporation stock a good choice for value investorsTrade Exit Report & Low Drawdown Momentum Trade Ideas - newser.com
Geron at Stifel 2025 Healthcare Conference: Strategic Adjustments for Rytelo - Investing.com
Geron Corp. Hits Day Low of $1.04 Amid Price Pressure - Markets Mojo
Geron Shrinks Quarterly Losses And Meets Revenue Goals - Finimize
Market reaction to Geron Corporation’s recent newsProfit Target & Community Consensus Trade Alerts - newser.com
Geron Corporation (NASDAQ:GERN) Q3 2025 Earnings Call Transcript - Insider Monkey
Geron: Q3 Earnings Snapshot - CT Insider
Will earnings trigger a reversal in Geron CorporationSwing Trade & Smart Investment Allocation Tips - newser.com
Aug Fed Impact: Can Geron Corporation stock deliver consistent earnings growthEarnings Trend Report & Reliable Breakout Stock Forecasts - Fundação Cultural do Pará
Can Geron Corporation stock sustain free cash flow growthEarnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
Geron Q3 2025 Earnings Call Transcript - MarketBeat
Geron Corp (GERN) Q3 2025 Earnings Call Highlights: Revenue Growth Amidst RYTELO Demand Challenges - Investing.com Canada
Geron Corporation (GERN) Q3 2025 Earnings Highlight RYTELO Devel - GuruFocus
Geron Corp Stock (GERN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):